Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Surv Ophthalmol. 2017 Dec 27;63(4):453–479. doi: 10.1016/j.survophthal.2017.12.008

Figure 15.

Figure 15

Subconjunctival delivery of bevacizumab diminishes opacity of corneal allografts in the high-risk setting. High-risk graft beds in BALB/c mice were transplanted with C57BL/6 cornea, and mice were left untreated (n = 10) or were treated topically (n = 10) or subconjunctivally (n = 10) with bevacizumab. Corneal allografts were examined regularly to 8 weeks after transplantation by slit lamp, and graft opacity was scored using a standard grading scheme. Student's t-test was performed to evaluate statistical significance (*P < 0.05; **P < 0.01).53 (Adapted from Dastjerdi et al with permission from IOVS)